IL153352A0 - Coumarin derivatives with comt inhibiting activity - Google Patents

Coumarin derivatives with comt inhibiting activity

Info

Publication number
IL153352A0
IL153352A0 IL15335201A IL15335201A IL153352A0 IL 153352 A0 IL153352 A0 IL 153352A0 IL 15335201 A IL15335201 A IL 15335201A IL 15335201 A IL15335201 A IL 15335201A IL 153352 A0 IL153352 A0 IL 153352A0
Authority
IL
Israel
Prior art keywords
sub
inhibiting activity
coumarin derivatives
comt
comt inhibiting
Prior art date
Application number
IL15335201A
Other languages
English (en)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of IL153352A0 publication Critical patent/IL153352A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15335201A 2000-07-03 2001-06-28 Coumarin derivatives with comt inhibiting activity IL153352A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20001593A FI20001593A (fi) 2000-07-03 2000-07-03 Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
PCT/FI2001/000613 WO2002002548A1 (en) 2000-07-03 2001-06-28 Coumarin derivatives with comt inhibiting activity

Publications (1)

Publication Number Publication Date
IL153352A0 true IL153352A0 (en) 2003-07-06

Family

ID=8558717

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15335201A IL153352A0 (en) 2000-07-03 2001-06-28 Coumarin derivatives with comt inhibiting activity
IL153352A IL153352A (en) 2000-07-03 2002-12-10 History of coumarin with inhibitory COMT action

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153352A IL153352A (en) 2000-07-03 2002-12-10 History of coumarin with inhibitory COMT action

Country Status (27)

Country Link
US (1) US6951870B2 (ru)
EP (1) EP1301503B1 (ru)
JP (1) JP4851051B2 (ru)
KR (1) KR20030040225A (ru)
CN (1) CN1199963C (ru)
AT (1) ATE260268T1 (ru)
AU (2) AU2001272597B9 (ru)
BG (1) BG107513A (ru)
BR (1) BR0111969A (ru)
CA (1) CA2414787C (ru)
DE (1) DE60102161T2 (ru)
DK (1) DK1301503T3 (ru)
EE (1) EE200300008A (ru)
ES (1) ES2215919T3 (ru)
FI (1) FI20001593A (ru)
HU (1) HUP0301706A3 (ru)
IL (2) IL153352A0 (ru)
MX (1) MXPA02012657A (ru)
NO (1) NO328699B1 (ru)
NZ (1) NZ523121A (ru)
PL (1) PL359068A1 (ru)
PT (1) PT1301503E (ru)
RU (1) RU2282627C2 (ru)
SK (1) SK18452002A3 (ru)
TR (1) TR200400802T4 (ru)
WO (1) WO2002002548A1 (ru)
ZA (1) ZA200210161B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2003265737B2 (en) * 2002-10-02 2008-10-16 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
MY148644A (en) * 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
PL3253208T3 (pl) 2015-02-02 2021-11-08 Mei Pharma, Inc. Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
CN108698984B (zh) 2015-12-18 2022-05-10 H·科斯特 用作药物、特别是用于治疗帕金森氏病的双环化合物
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5035393A (ru) * 1973-08-01 1975-04-04
US3973608A (en) 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB8816519D0 (en) 1987-07-23 1988-08-17 Ici Plc Antibiotic compounds
HUT63843A (en) 1992-02-13 1993-10-28 Biosignal Kutato Fejlesztoe Kf Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds
JP3166094B2 (ja) * 1993-09-08 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH0892157A (ja) 1994-05-02 1996-04-09 F Hoffmann La Roche Ag プルプロガリン誘導体
GB9626472D0 (en) 1996-12-20 1997-02-05 Aperia Anita C New use of comt inhibitors

Also Published As

Publication number Publication date
DK1301503T3 (da) 2004-06-28
ATE260268T1 (de) 2004-03-15
FI20001593A0 (fi) 2000-07-03
CN1199963C (zh) 2005-05-04
CA2414787C (en) 2010-12-14
IL153352A (en) 2009-05-04
NO328699B1 (no) 2010-04-26
FI20001593A (fi) 2002-01-04
JP4851051B2 (ja) 2012-01-11
NZ523121A (en) 2004-08-27
US20040110750A9 (en) 2004-06-10
HUP0301706A3 (en) 2005-12-28
EP1301503A1 (en) 2003-04-16
HUP0301706A2 (hu) 2003-09-29
EE200300008A (et) 2004-08-16
AU2001272597B9 (en) 2005-08-11
RU2282627C2 (ru) 2006-08-27
CN1440399A (zh) 2003-09-03
US6951870B2 (en) 2005-10-04
DE60102161D1 (de) 2004-04-01
NO20026095L (no) 2003-03-03
KR20030040225A (ko) 2003-05-22
BR0111969A (pt) 2003-07-01
ES2215919T3 (es) 2004-10-16
DE60102161T2 (de) 2004-09-16
JP2004502684A (ja) 2004-01-29
CA2414787A1 (en) 2002-01-10
TR200400802T4 (tr) 2004-07-21
EP1301503B1 (en) 2004-02-25
PL359068A1 (en) 2004-08-23
SK18452002A3 (sk) 2004-04-06
AU7259701A (en) 2002-01-14
MXPA02012657A (es) 2003-05-14
BG107513A (bg) 2003-06-30
ZA200210161B (en) 2004-03-15
AU2001272597B2 (en) 2005-07-21
NO20026095D0 (no) 2002-12-18
WO2002002548A1 (en) 2002-01-10
US20030186975A1 (en) 2003-10-02
PT1301503E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
AU7259701A (en) Coumarin derivatives with comt inhibiting activity
DK0931788T3 (da) Metalloproteasehæmmere
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
PL361355A1 (en) Phenylglycine derivatives
PT1044967E (pt) Inibidores da uroquinase do tipo 2-piridinilguanidina
AP2001002175A0 (en) Combination chemotherapy.
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
PL341239A1 (en) Dihydrobenzofuranes
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1096548A1 (en) Imidazopyridine-derivatives as inductible no-synthase inhibitors
ATE233264T1 (de) Polynalbuphinderivat
WO2004099130A3 (en) 1,2-diarylimidazoles useful as inhibitors of cox
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
BG105965A (en) C10 ester substituted taxanes and their application as antitumor agents
AU5846901A (en) New polycyclic indanylimidazoles with alpha2 adrenergic activity
TR200100222T2 (tr) Ürokinaz önleyicileri olarak izokinolinler
MXPA06004299A (es) Derivados de arilespirofuropiridina.
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations
EP1403250A4 (en) BIS DERIVATIVE (5-ARYL-2-PYRIDYL)
EP1300395A4 (en) 4-SUBSTITUTED PIPERIDINE CONNECTION
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.
HK1039451A1 (en) Use of catechol derivatives as proteinase inhibitors